Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SKA
|
|||
| Former ID |
DIB014627
|
|||
| Drug Name |
FCE-22716
|
|||
| Synonyms |
1-(6-Methylergolin-8beta-yl)hydantoin; 1-[[(8beta)-6-Methylergolin-8-yl]methyl]-2,4-imidazolidinedione; 7beta-(2,4,-Dioxo-1-imidazolidinylmethyl)-9-methyl-2,5balpha,6,7,8,9,9abeta,10-octahydroindolo[4,3a,3-f,g]quinoline; 8beta-(2,4-Dioxo-1-imidazolidinylmethyl)-6-methylergoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H22N4O2
|
|||
| Canonical SMILES |
CN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC5=O
|
|||
| InChI |
1S/C19H22N4O2/c1-22-8-11(9-23-10-17(24)21-19(23)25)5-14-13-3-2-4-15-18(13)12(7-20-15)6-16(14)22/h2-4,7,11,14,16,20H,5-6,8-10H2,1H3,(H,21,24,25)/t11-,14-,16-/m1/s1
|
|||
| InChIKey |
VXIHQTMCLKWCBN-DJSGYFEHSA-N
|
|||
| CAS Number |
CAS 95688-34-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Antagonist | [1], [2] |
| Adrenergic receptor alpha-1D (ADRA1D) | Target Info | Modulator | [1] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| cGMP-PKG signaling pathway | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| Adrenoceptors | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| Calcium Regulation in the Cardiac Cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92. | |||
| REF 2 | Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.